SecurityCMD / Cantel Medical Corp
IndustrySurgical and Medical Instruments and Apparatus
Common Stock Shares Outstanding41,714,903 shares (as of 2018-01-31)
Total Insiders21
Total Directors12
Total Officers11

Stock Insider Trading (from SEC Form 4)

Cantel Medical Corp insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CMD / Cantel Medical Corp insiders include BERMAN ANN E, COHEN JOSEPH M, Hansen Jorgen B, Capone Brian, Myers Ronnie, NODIFF ERIC W, DIKER CHARLES M, Krakauer Andrew A, FOTIADES GEORGE L, Conway Lawrence, and ANAYA STEVEN C, BATKIN ALAN R, Yellin Seth M, Pronovost Peter Diker Mark N., Donnelly-Brienza Dorothy A, SHELDON CRAIG A, Forese Laura L, SLOVIN BRUCE, Clifford Peter G, EVNIN ANTHONY B, .

Insider Roster

Insider Dir Off 10% Shares Owned
NODIFF ERIC W EVP and General Counsel
X 37,357
Myers Ronnie Director
X 2,058
Clifford Peter G EVP and CFO
X 14,172
Capone Brian VP and Princ. Accounting Ofr
X 2,123
DIKER CHARLES M Chairman, Director, 10% Owner
X X X 3,681,511
Diker Mark N. Director
X 471,122
Donnelly-Brienza Dorothy A SVP and Chief HR Officer
X 4,777
X 54,225
Yellin Seth M Executive Vice President
X 22,856
X 94,366
Conway Lawrence Senior Vice President
X 5,416
Pronovost Peter Director
X 39,221
Hansen Jorgen B President and COO
X 47,520
Forese Laura L Director
X 4,210
X 5,424
X 6,272
ANAYA STEVEN C SVP; Chief Accounting Officer
X 36,928
Krakauer Andrew A CEO, Director

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-05-15 4 NODIFF ERIC W F D 124.47 -2,197 37,357
2018-04-10 4 Myers Ronnie S D 108.261 -200 2,058 222,801
2018-04-17 4 Capone Brian F D 113.42 -173 2,123
2018-04-17 4 Clifford Peter G S D 114.8918 -1,250 14,172 1,628,247
2018-04-10 4 NODIFF ERIC W S D 108.3052 -1,275 39,556 4,284,120
2018-03-29 4 DIKER CHARLES M S D 111.7907 -5,070 3,681,511 411,558,692
2018-03-28 4 DIKER CHARLES M S D 110.6757 -4,246 3,686,581 408,014,933
2018-03-27 4 DIKER CHARLES M S D 113.1481 -2,584 3,690,827 417,610,062
2018-03-23 4 Clifford Peter G F D 113.03 -804 15,422
2018-03-13 4 DIKER CHARLES M S D 115.4889 -9,500 3,693,411 426,547,974
2018-03-12 4 DIKER CHARLES M S D 117.0974 -9,000 3,702,911 433,601,251
2018-03-09 4 DIKER CHARLES M S D 119.1083 -1,500 3,711,911 442,119,409
2018-01-23 4 NODIFF ERIC W S D 112.2143 -1,000 40,831 4,581,822
2018-01-18 4 Diker Mark N. S D 112.0895 -2,000 471,122 52,807,829
2018-01-17 4 Diker Mark N. S D 111.556 -3,000 473,122 52,779,598
2018-01-16 4 DIKER CHARLES M S D 110.9564 -10,000 3,713,411 412,026,716
2018-01-11 4 DIKER CHARLES M S D 107.2575 -5,700 3,723,411 399,363,755
2018-01-09 4 DIKER CHARLES M S D 107.0541 -4,278 3,729,111 399,216,622
2018-01-03 4 Donnelly-Brienza Dorothy A F D 101.35 -533 4,777
2017-12-29 4 Yellin Seth M S D 103.5764 -1,000 22,856 2,367,342
2017-12-28 4 BATKIN ALAN R G D -10,000 54,225
2017-12-27 4 DIKER CHARLES M S D 102.421 -3,000 3,086,386 316,110,741
2017-12-26 4 DIKER CHARLES M By custodial accounts for benefit of grandchildren G I 1,040 115,924
2017-12-26 4 DIKER CHARLES M G D -1,300 511,098
2017-12-26 4 DIKER CHARLES M By wife G I -1,300 511,098
2017-12-26 4 DIKER CHARLES M S D 102.1019 -5,000 3,090,686 315,564,913
2017-12-22 4 DIKER CHARLES M S D 101.1022 -10,000 3,095,686 312,980,665
2017-10-30 4 DIKER CHARLES M By trust for benefit of children J I -106,000 137,701
2017-12-26 4 Diker Mark N. By custodial account for children G I 520 47,724
2017-12-26 4 Diker Mark N. G D 260 428,398
2017-12-21 4 Diker Mark N. G D -1,459 428,138
2017-12-21 4 BATKIN ALAN R G D -7,000 64,225
2017-12-19 4 DIKER CHARLES M S D 100.4299 -2,000 3,858,949 387,553,862
2017-12-18 4 DIKER CHARLES M S D 100.5447 -10,000 3,860,949 388,197,959
2017-12-18 4 FOTIADES GEORGE L S D 101.085 -5,700 94,366 9,538,987
2017-10-23 4 NODIFF ERIC W G D -177 41,831
2017-10-18 4 DIKER CHARLES M F D 95.42 -613 3,870,949
2017-10-20 4 NODIFF ERIC W By wife S I 97.545 -2,868 42,008 4,097,670
2017-10-16 4 Yellin Seth M F D 96.46 -442 23,856
2017-10-13 4 FOTIADES GEORGE L S D 95.231 -6,000 100,066 9,529,385
2017-10-12 4 Yellin Seth M F D 95.07 -555 24,298
2017-10-10 4 Yellin Seth M F D 96.46 -1,252 24,853
2017-10-10 4 Donnelly-Brienza Dorothy A A D 1,500 5,310
2017-10-10 4 FOTIADES GEORGE L A D 520 106,066
2017-10-10 4 Capone Brian A D 895 2,296
2017-10-12 4 Hansen Jorgen B F D 95.07 -1,606 47,520
2017-10-10 4 Hansen Jorgen B F D 96.46 -4,287 49,126
2017-10-10 4 Hansen Jorgen B A D 636 53,413
2017-10-10 4 Hansen Jorgen B A D 7,780 52,777
2017-10-12 4 Clifford Peter G F D 95.07 -843 16,120
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?

2018-04-24 zacks
Looking for broad exposure to the Small Cap Growth segment of the US equity market? You should consider the Vanguard S&P Small-Cap 600 Growth ETF (VIOG - Free Report) , a passively managed exchange traded fund launched on 09/09/2010. (20-0)

BRIEF-Cantel Medical Acquires Aexis Medical

2018-03-21 reuters

Cantel Medical's (CMD) CEO Jorgen Hansen on Q2 2018 Results - Earnings Call Transcript

2018-03-10 seekingalpha
Greetings and welcome to the Cantel Medical Corp Second Quarter Fiscal 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Milicent Brooks, Director of Corporate Communications for Cantel Medical Corp. Thank you. You may begin. (42-0)

Cantel Medical Corporation 2017 Q4 - Results - Earnings Call Slides

2018-03-09 seekingalpha
The following slide deck was published by Cantel Medical Corporation in conjunction with their 2017 Q4 earnings call. (8-0)

When Markets Correct, Many Fear, But Few Listen

2018-02-27 seekingalpha
When there’s not much to say, sometimes it’s prudent to not say anything at all. However, due to the volatility over the last month, it seems necessary to break the silence, evaluate what is currently occurring, and put some perspective on what is expected moving forward. Inevitably, when markets correct, something is changing and we ought to try and identify what that is. (877-2)